NCT04720443 is a Phase 1 clinical trial of NIP292 tablet in Idiopathic Pulmonary Fibrosis, sponsored by The National Institutes of Pharmaceutical R&D Co. Ltd, China.

Who is sponsoring NCT04720443?

NCT04720443 is sponsored by The National Institutes of Pharmaceutical R&D Co. Ltd, China.

What drugs are being tested in NCT04720443?

Interventions in NCT04720443: NIP292 tablet, NIP292 tablet, NIP292 tablet, NIP292 tablet, NIP292 tablet, NIP292 tablets, NIP292 tablets.

What condition does NCT04720443 study?

NCT04720443 studies Idiopathic Pulmonary Fibrosis.

Is NCT04720443 still recruiting?

NCT04720443 is currently completed. Last updated 24 March 2023.

Last reviewed 2023-03-24 · How we verify

NCT04720443

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Safety, Tolerability, and Pharmacokinetic Study of NIP292 in Healthy Normal Subjects

Completed Phase 1 Last updated 24 March 2023

What this trial tests

Phase 1 trial testing NIP292 tablet in Idiopathic Pulmonary Fibrosis in 56 participants. Completed in 14 July 2022.

Timeline

22 November 2019

Primary endpoint
14 July 2022

14 July 2022

Quick facts

Lead sponsor	The National Institutes of Pharmaceutical R&D Co. Ltd, China
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	sequential
Masking	double
Primary purpose	treatment
Enrollment	56
Start date	22 November 2019
Primary completion	14 July 2022
Estimated completion	14 July 2022
Sites	1 location across United States

Drugs / interventions tested

NIP292 tablet — full drug profile →
NIP292 tablet — full drug profile →
NIP292 tablet — full drug profile →
NIP292 tablet — full drug profile →
NIP292 tablet — full drug profile →
NIP292 tablets — full drug profile →
NIP292 tablets — full drug profile →

Conditions studied

Idiopathic Pulmonary Fibrosis — all drugs for Idiopathic Pulmonary Fibrosis →

Sponsor

The National Institutes of Pharmaceutical R&D Co. Ltd, China

Who can join

Adults 18 to 55, any sex, with Idiopathic Pulmonary Fibrosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is being conducted to evaluate the safety and tolerability of single ascending and multiple ascending oral doses of NIP292 tablets administered following an overnight fast in healthy adult subjects.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Regeneration or Repair? The Role of Alveolar Epithelial Cells in the Pathogenesis of Idiopathic Pulmonary Fibrosis (IPF).
Confalonieri P, Volpe MC, Jacob J, Maiocchi S, et al · · 2022 · cited 106× · PMID 35805179 · DOI 10.3390/cells11132095
Vascular involvement in idiopathic pulmonary fibrosis.
Mondoni M, Rinaldo R, Ryerson CJ, Albrici C, et al · · 2024 · cited 6× · PMID 39588083 · DOI 10.1183/23120541.00550-2024

Verify or expand the search:

Other recruiting trials for Idiopathic Pulmonary Fibrosis

Currently open trials in the same condition.

NCT05988463 — Dose-Escalation Study of Artesunate Patients With IPF · Phase 1 · recruiting
NCT06241560 — A Study in People With Idiopathic Pulmonary Fibrosis to Test Whether Pirfenidone Influences the Amount of BI 1015550 in · Phase 2 · recruiting
NCT07407543 — A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SRN001 in Healthy Korean and Cauc · Phase 1 · recruiting
NCT07036523 — A Study to Find Out Whether BI 765423 Has an Effect on Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF) · Phase 2 · recruiting
NCT07225296 — A Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics o · Phase 1 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04720443 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by The National Institutes of Pharmaceutical R&D Co. Ltd, China
Last refreshed: 24 March 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04720443.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing